|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Mikula-Pietrasik J, Niklas A, Uruski P,
Tykarski A and Ksiazek K: Mechanisms and significance of
therapy-induced and spontaneous senescence of cancer cells. Cell
Mol Life Sci. 77:213–229. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Faheem MM, Seligson ND, Ahmad SM, Rasool
RU, Gandhi SG, Bhagat M and Goswami A: Convergence of
therapy-induced senescence (TIS) and EMT in multistep
carcinogenesis: Current opinions and emerging perspectives. Cell
Death Discov. 6:512020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takasugi M, Yoshida Y and Ohtani N:
Cellular senescence and the tumour microenvironment. Mol Oncol.
16:3333–3351. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang L, Lankhorst L and Bernards R:
Exploiting senescence for the treatment of cancer. Nat Rev Cancer.
22:340–355. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McHugh D, Duran I and Gil J: Senescence as
a therapeutic target in cancer and age-related diseases. Nat Rev
Drug Discov. 24:57–71. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan W, Tan Y, Chen X, Zeng L, Lv Y and
Yang J: miRNA-204-5p acts as a tumor suppressor in gastric cancer
by inhibiting cell migration, invasion, and glycolysis via the
RAB22A/PI3K/AKT axis. Sci Rep. 15:295362025. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan S, Hu X, Wu Y, Ye W, Zhu Y, He Y, Zhan
F, Wu W and Ma Z: ITGA4 contributes to 5-fluorouracil resistance by
Up-Regulating PI3K/AKT signaling: evidence from network
pharmacology, molecular docking and experimental verification. Drug
Des Devel Ther. 19:4105–4122. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fontana F, Giannitti G, Marchesi S and
Limonta P: The PI3K/Akt pathway and glucose metabolism: A dangerous
liaison in cancer. Int J Biol Sci. 20:3113–3125. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang CY, Tan XH, Yang HH, Jin L, Hong JR,
Zhou Y and Huang XT: COX-2/sEH dual inhibitor alleviates hepatocyte
senescence in NAFLD mice by restoring autophagy through
Sirt1/PI3K/AKT/mTOR. Int J Mol Sci. 23:82672022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang Q, Markby GR, MacNair AJ, Tang K,
Tkacz M, Parys M, Phadwal K, MacRae VE and Corcoran BM:
TGF-β-induced PI3K/AKT/mTOR pathway controls myofibroblast
differentiation and secretory phenotype of valvular interstitial
cells through the modulation of cellular senescence in a naturally
occurring in vitro canine model of myxomatous mitral valve disease.
Cell Prolif. 56:e134352023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Efimova EV, Appelbe OK, Ricco N, Lee SS,
Liu Y, Wolfgeher DJ, Collins TN, Flor AC, Ramamurthy A, Warrington
S, et al: O-GlcNAcylation enhances double-strand break repair,
promotes cancer cell proliferation, and prevents therapy-induced
senescence in irradiated tumors. Mol Cancer Res. 17:1338–1350.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gu J, Wang J, Liu X, Sai K, Mai J, Xing F,
Chen Z, Yang X, Lu W, Guo C, et al: IL-6 derived from
therapy-induced senescence facilitates the glycolytic phenotype in
glioblastoma cells. Am J Cancer Res. 11:458–478. 2021.PubMed/NCBI
|
|
14
|
Mikula-Pietrasik J, Witucka A, Pakula M,
Uruski P, Begier-Krasinska B, Niklas A, Tykarski A and Ksiazek K:
Comprehensive review on how platinum- and taxane-based chemotherapy
of ovarian cancer affects biology of normal cells. Cell Mol Life
Sci. 76:681–697. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Melones-Herrero J, Alcala S, Ruiz-Canas L,
Benitez-Buelga C, Batres-Ramos S, Cales C, Lorenzo O, Perona R,
Quiroga AG, Sainz B Jr and Sanchez-Perez I: Platinum iodido drugs
show potential anti-tumor activity, affecting cancer cell
metabolism and inducing ROS and senescence in gastrointestinal
cancer cells. Commun Biol. 7:3532024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: an enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47((W1)): W556–W560.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee BY, Han JA, Im JS, Morrone A, Johung
K, Goodwin EC, Kleijer WJ, DiMaio D and Hwang ES:
Senescence-associated beta-galactosidase is lysosomal
beta-galactosidase. Aging Cell. 5:187–195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan J, Chen S, Yi Z, Zhao R, Zhu J, Ding S
and Wu J: The role of p21 in cellular senescence and aging-related
diseases. Mol Cells. 47:1001132024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Biran A, Zada L, Abou Karam P, Vadai E,
Roitman L, Ovadya Y, Porat Z and Krizhanovsky V: Quantitative
identification of senescent cells in aging and disease. Aging Cell.
16:661–671. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong Z, Luo Y, Yuan Z, Tian Y, Jin T and
Xu F: Cellular senescence and SASP in tumor progression and
therapeutic opportunities. Mol Cancer. 23:1812024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gorgoulis V, Adams PD, Alimonti A, Bennett
DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K,
Ferbeyre G, et al: Cellular senescence: Defining a path forward.
Cell. 179:813–827. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma YL, Kong CY, Guo Z, Wang MY, Wang P,
Liu FY, Yang D, Yang Z and Tang QZ: Semaglutide ameliorates cardiac
remodeling in male mice by optimizing energy substrate utilization
through the Creb5/NR4a1 axis. Nat Commun. 15:47572024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li JM, Song ZH, Li Y, Chen HW, Li H, Yuan
L, Li J, Lv WY, Liu L and Wang N: NR4A1 silencing alleviates
high-glucose-stimulated HK-2 cells pyroptosis and fibrosis via
hindering NLRP3 activation and PI3K/AKT pathway. World J Diabetes.
16:975442025.PubMed/NCBI
|
|
25
|
Kallenbach J, Atri Roozbahani G, Heidari
Horestani M and Baniahmad A: Distinct mechanisms mediating
therapy-induced cellular senescence in prostate cancer. Cell
Biosci. 12:2002022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang D, Zhang JW, Xu H, Chen X, Gao Y,
Jiang HG, Wang Y, Wu H, Yang L, Wang WB, et al: Therapy-induced
senescent tumor cell-derived extracellular vesicles promote
colorectal cancer progression through SERPINE1-mediated NF-ĸB p65
nuclear translocation. Mol Cancer. 23:702024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang H, Wei Z, Xu C, Fang F, Wang Z, Zhong
Y and Wang X: Nuclear receptor 4A1 ameliorates UUO-induced renal
fibrosis by inhibiting the PI3K/AKT pathway. Sci Rep. 14:247872024.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lei L, Guo Q, Cheng Y, Gui Y, Li W, Zhao
Y, Xu Z, Luo Y, Wu G, Wang JZ, et al: Age-dependent elevation of
Nr4a1 attenuates PI3K/AKT/GSK3beta pathway and mediates tau
hyperphosphorylation and cognitive impairments. J Adv Res.
S2090-1232(25)00442-4. 2025.(Epub ahead of print).
|
|
29
|
Kirkland JL and Tchkonia T: Cellular
senescence: A translational perspective. EBioMedicine. 21:21–28.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Herranz N and Gil J: Mechanisms and
functions of cellular senescence. J Clin Invest. 128:1238–1246.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Safe S and Karki K: The paradoxical roles
of orphan nuclear receptor 4A (NR4A) in cancer. Mol Cancer Res.
19:180–191. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma QX, Yin M and Lei QY: A nucleotide
regulates NR4A1 status in gastric cancer. Mol Cell. 85:4299–4300.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Faget DV, Ren Q and Stewart SA: Unmasking
senescence: Context-dependent effects of SASP in cancer. Nat Rev
Cancer. 19:439–453. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang C, Vegna S, Jin H, Benedict B,
Lieftink C, Ramirez C, de Oliveira RL, Morris B, Gadiot J, Wang W,
et al: Inducing and exploiting vulnerabilities for the treatment of
liver cancer. Nature. 574:268–272. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qing Y, Li H, Zhao Y, Hu P, Wang X, Yu X,
Zhu M, Wang H, Wang Z, Guo Q and Hui H: One-Two punch therapy for
the treatment of T-Cell malignancies involving p53-dependent
cellular senescence. Oxid Med Cell Longev. 2021:55295182021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang T, Liu W, Shen Q, Tao R, Li C, Shen
Q, Lin Y, Huang Y, Yang L, Xie G, et al: Combination of PARP
inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent
therapy-induced senescence and provides ‘one-two punch’ opportunity
with anti-PD-L1 therapy in colorectal cancer. Cancer Sci.
114:4184–4201. 2023. View Article : Google Scholar : PubMed/NCBI
|
